APA (7th ed.) Citation

Y, Y., J, C., C, H., Y, Z., J, W., Y, S., . . . L, Z. (2019). A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer. Journal of thoracic disease, 11(8), 3347. https://doi.org/10.21037/jtd.2019.08.22

Chicago Style (17th ed.) Citation

Y, Yang, et al. "A Randomised, Multicentre Open-label Phase II Study to Evaluate the Efficacy, Tolerability and Pharmacokinetics of Oral Vinorelbine Plus Cisplatin Versus Intravenous Vinorelbine Plus Cisplatin in Chinese Patients with Chemotherapy-naive Unresectable or Metastatic Non-small Cell Lung Cancer." Journal of Thoracic Disease 11, no. 8 (2019): 3347. https://doi.org/10.21037/jtd.2019.08.22.

MLA (9th ed.) Citation

Y, Yang, et al. "A Randomised, Multicentre Open-label Phase II Study to Evaluate the Efficacy, Tolerability and Pharmacokinetics of Oral Vinorelbine Plus Cisplatin Versus Intravenous Vinorelbine Plus Cisplatin in Chinese Patients with Chemotherapy-naive Unresectable or Metastatic Non-small Cell Lung Cancer." Journal of Thoracic Disease, vol. 11, no. 8, 2019, p. 3347, https://doi.org/10.21037/jtd.2019.08.22.